Avalun
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Avalun - overview
Established
2013
Location
Grenoble, -, France
Primary Industry
Healthcare
About
Avalun is a biotechnology company focused on developing innovative rapid diagnostic solutions for healthcare professionals, enhancing medical decision-making across diverse clinical environments. Founded in 2013, Avalun specializes in the advancement of rapid diagnostic technologies. The company, headquartered in Grenoble, France, has participated in a single funding deal, which occurred in July 2015 when it was acquired by Remora Capital for an undisclosed amount. The CEO is Vincent Poher, while Samira Taheri serves as the founder.
Avalun provides a range of rapid diagnostic tests designed for immediate clinical use, enabling healthcare professionals to make timely decisions. Their offerings include point-of-care tests and solutions for molecular diagnostics, catering to various healthcare settings such as hospitals and laboratories, aimed at improving patient management. In the year 2021, Avalun reported a revenue of USD 888,864. 80, with an EBITDA of USD -1,010,402 for the same year.
The company's revenue generation primarily stems from its sales of rapid diagnostic tests to healthcare institutions, facilitated through B2B transactions. Avalun aims to leverage its recent acquisition to fuel growth by developing new diagnostic products and expanding into international markets. Plans are underway to introduce innovative testing solutions aimed at enhancing healthcare outcomes. The company is strategically targeting growth in the European and North American markets, with an emphasis on increasing distribution partnerships by 2025.
The recent acquisition will provide the necessary resources to support these initiatives, further solidifying Avalun's market presence.
Current Investors
Remora Capital
Primary Industry
Healthcare
Sub Industries
Diagnostic, Medical & Imaging Laboratories
Website
http://www.avalun.com
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Avalun - timeline of key events
Avalun - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 462,890 | 154,974 | 257,149 | 536,270 | 522,505 | 751,369 | - | - | - |
| % Revenue Growth (YoY) | - | (66.5%) | 65.9% | 108.5% | (2.6%) | 43.8% | - | - | - |
| EBITDA (USD) | (15,340) | (522,961) | (728,947) | (860,551) | (234,252) | (854,106) | - | - | - |
| Operating Income (USD) | (1,007,953) | (1,092,756) | (1,433,769) | (1,537,544) | (843,080) | (2,027,136) | - | - | - |
| Operating Margin | (217.8%) | (705.1%) | (557.6%) | (286.7%) | (161.4%) | (269.8%) | - | - | - |
| % EBITDA Margin | (3.3%) | (337.5%) | (283.5%) | (160.5%) | (44.8%) | (113.7%) | - | - | - |
| NET Income (USD) | (585,775) | (792,658) | (1,216,034) | (1,342,612) | (529,694) | (2,771,346) | - | - | - |
| % Net Margin | (126.5%) | (511.5%) | (472.9%) | (250.4%) | (101.4%) | (368.8%) | - | - | - |
Avalun - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | Avalun | - |
Displaying 1 - 1 of 1
Avalun - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.